Summary of base case and alternative scenario results
| Costs | Base case | Alternative scenario | ||||
| FPE | Non-FPE | Incremental | FPE | Non-FPE | Incremental | |
| Treatment (€) | 9086 | 10 432 | −1346 | 9086 | 10 432 | −1346 |
| Adverse event costs (€) | 269 | 582 | −313 | 238 | 551 | −314 |
| Acute costs (€) | 5259 | 5353 | −94 | 5250 | 5387 | −137 |
| Long term care costs (€) | 79 296 | 94 263 | −14 968 | 78 039 | 98 469 | −20 430 |
| Long term care costs (with nursing/residential care cost) (€) | 144 072 | 172 527 | −28 456 | 141 678 | 184 487 | −42 809 |
| Recurrent stroke costs (€) | 3297 | 3160 | 137 | 3313 | 2997 | 316 |
| Total costs (€) | 97 206 | 113 790 | −16 583 | 95 925 | 117 836 | −21 910 |
| NMB (€) | 52 634 | 74 306 | ||||
| Total costs (with nursing/residential care cost) (€) | 161 982 | 192 054 | −30 072 | 159 565 | 203 854 | −44 289 |
| NMB (with nursing/residential care cost) (€) | 66 122 | 96 684 | ||||
| Total QALYs | 7.89 | 6.69 | 1.2 | 7.96 | 6.21 | 1.75 |
| Total life years | 10.99 | 10.06 | 0.92 | 11.03 | 9.71 | 1.32 |
FPE, first pass effect; NMB, net monetary benefit; QALYs, quality-adjusted life-years.